DIABETIC NEPHROPATHY: DOES ANGIOTENSIN-CONVERTING ENZYME INHIBITORS MAINTAIN PRIORITY POSITION?


Cite item

Full Text

Abstract

The article is dedicated to the significance of ACE inhibitors in the treatment and prevention of diabetic nephropathy. Administration of ACE inhibitors in diabetes mellitus (DM) is closely reasoned by pathophysiology. Positive effect of this class of drugs on the prognosis of type 2 diabetes combined with arterial hypertension was confirmed by controlled trials, including high-risk patients. Evidences of effect of ACE inhibitors on microalbuminuria have been obtained in clinical studies, which used lisinopril. Considerable experience of use of lisinopril in patients with DNP allow to consider the drug as a priority ACE inhibitor used for treatment and prevention of kidney damage in diabetes mellitus, especially type 2 diabetes mellitus. Well-tested medications of lisinopril, which are characterized by favorable cost/effectiveness ratio, include, in particular, Lizigamma manufactured by pharmaceutical company Wörwag Pharma (Germany).

References

  1. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007;115(2):69-84.
  2. Шестакова М.В., Сунцов Ю.И., Дедов И.И. Диабетическая нефропатия: состояние проблемы в мире и в России // Сахарный диабет. 2001. № 3. C. 2-4.
  3. Дедов М.В., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М., 2006.
  4. Маслова О.В., Сунцов Ю.И., Шестакова М.В. и др. Распространенность диабетической нефропатии и хронической болезни почек при сахарном диабете в Российской Федерации // Клин. нефрология. 2010. № 3. C. 45-50.
  5. Pedro RA, Ramon SA, Marc BB. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-East of Spain, a population-based study. Ophthalmic Epidemiol 2010;17(4):251-65.
  6. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005;48(1):17-26.
  7. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(2):64-78.
  8. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317:705-13.
  9. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92.
  10. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Качество профилактики и лечения сердечно-сосудистых заболеваний и их осложнений у больных сахарным диабетом 2 типа в амбулаторных условиях // Кардиоваскулярная терапия и профилактика. 2008. № 7(7). C. 9-14.
  11. Mourad JJ, Le Jeune S. Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress. J Hypertens Suppl 2008;26(3):7-13.
  12. Wolf G. Molecular mechanisms of angiotensin II in the kidney; emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998;13:1131-142.
  13. Folii F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 1999;107:133-39.
  14. De Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int 2004;66:2109-18.
  15. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004;19:778-81.
  16. Шестакова М.В., Кочемасова Т.В., Горелышева В.А. и др. Роль молекул адгезии (ICAM-1 и Е-селектин) в развитии диабетических микроангиопатий // Тер. архив. 2002. № 6. C. 24-27.
  17. Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol 2004;19:480-87.
  18. Шестакова М.В. Нефропротекция: роль артериального давления в прогрессировании патологии почек. Зависит ли нефропротективный эффект от выбора антигипертензивного препарата? // Тер. архив. 2001. № 6. C. 64-66.
  19. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-59.
  20. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998;21(1):104-10.
  21. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349(9068):1787-92.
  22. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998;47(9):1507-11.
  23. Rangemark C, Lind H, Lindholm L, et al. Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension. Eur J Clin Pharmacol 1996;49(4):267-71.
  24. Tuominen JA, Ebeling P, Koivisto VA. Long-term lisinopril therapy reduces exercise-induced albuminuria in normoalbuminuric normotensive IDDM patients. Diabetes Care 1998;21(8):1345-48.
  25. Poulsen PL, Ebbehøj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study. J Intern Med 2001;249(5):433-40.
  26. Leoncini G, Martinoli C, Viazzi F, et al. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron 2002;90(2):169-73.
  27. Комитет экспертов РМОАГ. ВНОК. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК // Системные гипертензии. 2010. № 3. C. 5-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies